JP6978015B1 - Composition for skin application to increase the expression of CCN1 and CCN2 - Google Patents
Composition for skin application to increase the expression of CCN1 and CCN2 Download PDFInfo
- Publication number
- JP6978015B1 JP6978015B1 JP2020111472A JP2020111472A JP6978015B1 JP 6978015 B1 JP6978015 B1 JP 6978015B1 JP 2020111472 A JP2020111472 A JP 2020111472A JP 2020111472 A JP2020111472 A JP 2020111472A JP 6978015 B1 JP6978015 B1 JP 6978015B1
- Authority
- JP
- Japan
- Prior art keywords
- less
- ccn1
- ccn2
- extract
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 title claims abstract description 32
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 title claims abstract 4
- 102000005889 Cysteine-Rich Protein 61 Human genes 0.000 title claims abstract 4
- 239000000284 extract Substances 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 240000005605 Clitoria ternatea Species 0.000 claims abstract description 23
- 235000008358 Clitoria ternatea Nutrition 0.000 claims abstract description 22
- 230000001737 promoting effect Effects 0.000 claims description 18
- 210000002950 fibroblast Anatomy 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 14
- 230000029663 wound healing Effects 0.000 claims description 12
- 210000001339 epidermal cell Anatomy 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 38
- 240000002390 Pandanus odoratissimus Species 0.000 abstract description 12
- 238000010586 diagram Methods 0.000 abstract 1
- 102100031168 CCN family member 2 Human genes 0.000 description 28
- 102100031171 CCN family member 1 Human genes 0.000 description 27
- 239000000469 ethanolic extract Substances 0.000 description 27
- 210000003491 skin Anatomy 0.000 description 21
- 241000196324 Embryophyta Species 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- 241000233929 Pandanaceae Species 0.000 description 18
- 239000011259 mixed solution Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 14
- 238000002156 mixing Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 230000009759 skin aging Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 230000003779 hair growth Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 210000001626 skin fibroblast Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 4
- 210000002514 epidermal stem cell Anatomy 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 102000039854 CCN family Human genes 0.000 description 2
- 108091068251 CCN family Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 101150042405 CCN1 gene Proteins 0.000 description 1
- 241000157281 Clitoria Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 241000233930 Pandanus Species 0.000 description 1
- 235000005308 Pandanus Nutrition 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Abstract
【課題】 CCN1及びCCN2の発現を増加させるための皮膚適用用の新規組成物を提供すること。【解決手段】 チョウマメの水抽出物若しくは10%未満のアルコール抽出物、及びニオイタコノキの水抽出物若しくは10%未満のアルコール抽出物のいずれか一方又は両方を含む、CCN1及びCCN2の発現を増加させるための、皮膚適用用組成物。【選択図】 なしPROBLEM TO BE SOLVED: To provide a novel composition for skin application for increasing the expression of CCN1 and CCN2. It increases the expression of CCN1 and CCN2, which comprises water extract of Clitoria ternatea or less than 10% alcohol extract and / or both of water extract of Pandan or less than 10% alcohol extract. Composition for skin application. [Selection diagram] None
Description
本開示は、CCN1及びCCN2の発現を増加させるための皮膚適用用組成物に関する。 The present disclosure relates to a composition for skin application to increase the expression of CCN1 and CCN2.
皮膚は、最表層から表皮、真皮及び皮下組織により構成される。表皮は、外的環境から身体を保護し、その健全な状態を確保する役割を担っている。表皮は、また、微生物や化学物質の侵入を抑制し、且つ水分の蒸発を防ぐことで皮膚の乾燥を防止する役割も果たす。 The skin is composed of the epidermis, the dermis and the hypodermis from the outermost layer. The epidermis plays a role in protecting the body from the external environment and ensuring its healthy condition. The epidermis also plays a role in preventing the skin from drying out by suppressing the invasion of microorganisms and chemical substances and preventing the evaporation of water.
真皮は、線維芽細胞、組織球・マクロファージ、肥満細胞、及び形質細胞から構成される。線維芽細胞は、コラーゲン、エラスチン、ヒアルロン酸などを産生する細胞であり、コラーゲンを繊維束として真皮構造を形成する役割を担っている。線維芽細胞は、また、皮膚組織に損傷が加わると損傷部に遊走し、コラーゲンなどの細胞外マトリックスの産生を開始する役割を担っている。これらの役割により、線維芽細胞は、創傷治癒の過程において重要な役割を担っている。 The dermis is composed of fibroblasts, tissue spheres / macrophages, mast cells, and plasma cells. Fibroblasts are cells that produce collagen, elastin, hyaluronic acid, etc., and play a role in forming the dermis structure with collagen as a fiber bundle. Fibroblasts also play a role in migrating to the injured area when the skin tissue is damaged and initiating the production of extracellular matrix such as collagen. Due to these roles, fibroblasts play an important role in the process of wound healing.
線維芽細胞は、さらに、紫外線、乾燥、ストレス、及び老化などの影響によって増殖能が低下する。このため、線維芽細胞の増殖能に影響があると、皮膚の弾力低下など肌の老化の原因となり、又は創傷治癒の速度が遅くなり得る。 Fibroblasts are further reduced in proliferative capacity by the effects of UV light, desiccation, stress, and aging. Therefore, if the proliferative ability of fibroblasts is affected, it may cause skin aging such as a decrease in skin elasticity, or the rate of wound healing may be slowed down.
線維芽細胞の増殖を活性化させるための研究が報告されている(特許文献1)。 Studies for activating the proliferation of fibroblasts have been reported (Patent Document 1).
本開示は、新規な皮膚適用用の新規組成物を提供することを目的とする。 The present disclosure is intended to provide novel compositions for novel skin applications.
本開示は、以下の発明を提供する:
[項1]
チョウマメの水抽出物若しくは10%未満のアルコール抽出物、及びニオイタコノキの水抽出物若しくは10%未満のアルコール抽出物のいずれか一方又は両方を含む、CCN1及びCCN2の発現を増加させるための、皮膚適用用組成物。
[項2]
肌の老化防止用、創傷治癒用、又は発毛促進用である、項1に記載の組成物。
[項3]
表皮幹細胞から表皮角化細胞への分化促進、或いは表皮幹細胞及び/又は表皮角化細胞の増殖促進による肌の老化防止用;線維芽細胞の増殖促進による創傷治癒用;又は毛包幹細胞から毛乳頭細胞への分化促進、或いは毛包幹細胞及び/又は毛乳頭細胞の増殖促進による発毛促進用である、項2に記載の組成物。
[項4]
チョウマメの水抽出物を含む、項1〜3のいずれか一項に記載の組成物。
[項5]
ニオイタコノキの水抽出物を含む、項1〜3のいずれか一項に記載の組成物。
[項6]
前記チョウマメの10%未満のアルコール抽出物が、チョウマメの10%未満のエタノール抽出物であり、及びニオイタコノキの10%未満のアルコール抽出物が、ニオイタコノキの10%未満のエタノール抽出物である、項1〜3のいずれか一項に記載の組成物。
The present disclosure provides the following inventions:
[Item 1]
Skin for increasing expression of CCN1 and CCN2, comprising water extract of Clitoria ternatea or less than 10% alcohol extract and / or both of water extract of Pandan or less than 10% alcohol extract. Composition for application.
[Item 2]
[Item 3]
For promoting skin differentiation from epidermal stem cells to epidermal keratinocytes, or for preventing skin aging by promoting proliferation of epidermal stem cells and / or epidermal keratinocytes; for wound healing by promoting proliferation of fibroblasts; or from hair follicle stem cells to
[Item 4]
[Item 5]
[Item 6]
Less than 10% alcohol extract of the butterfly bean is less than 10% ethanol extract of Pandan, and less than 10% alcohol extract of Pandan is less than 10% ethanol extract of Pandan.
「チョウマメ(Clitoria ternatea L.)」は、チョウマメ属(Clitoria)のチョウマメ属(C. ternatea)に属するマメ科の植物である。チョウマメは、例えば、公知の方法により栽培及び採取でき、又は商業的に入手可能である。1つの実施形態において、チョウマメは、花、葉、茎、及び根からなる群から選択される少なくとも1つの部位であってよく、好ましくは花、及び葉のいずれか一方又は両方であり、より好ましくは花である。チョウマメの重量は、乾燥形態の重量である。 "Clitoria ternatea L." is a leguminous plant belonging to the genus C. ternatea of the genus Clitoria. Clitoria ternatea can be cultivated and harvested, for example, by known methods, or is commercially available. In one embodiment, the Clitoria ternatea may be at least one site selected from the group consisting of flowers, leaves, stems, and roots, preferably one or both of the flowers and leaves, more preferably. Is a flower. The weight of Clitoria ternatea is the weight of the dried form.
チョウマメの水抽出物は、例えば、チョウマメの粉砕物と水とを混合し、得られた混合液から遠心分離又は濾過などの分離方法によって固形物を分離及び除去することによって得ることができる。1つの実施形態において、チョウマメ(好ましくは花の乾燥物)の水抽出物は、チョウマメの粉砕物と、前記粉砕物の10倍重量の水とを混合し、得られた混合液を室温で20分間放置した後、遠心分離又は濾過などの分離方法によって前記混合液から固形物を分離及び除去することによって得ることができる。チョウマメの水抽出物は、液体又は固体であってよい。チョウマメの水抽出物(固体)は、例えば、チョウマメの水抽出物(液体)の凍結乾燥によって調製することができる。 The water extract of Clitoria ternatea can be obtained, for example, by mixing pulverized C. elegans and water, and separating and removing the solid matter from the obtained mixture by a separation method such as centrifugation or filtration. In one embodiment, the water extract of Clitoria ternatea (preferably dried flower) is obtained by mixing the pulverized C. elegans and 10 times the weight of water of the pulverized product, and the resulting mixed solution is 20 at room temperature. It can be obtained by separating and removing the solid matter from the mixed solution by a separation method such as centrifugation or filtration after leaving it for a minute. The water extract of Clitoria ternatea may be liquid or solid. The water extract of Clitoria ternatea (solid) can be prepared, for example, by freeze-drying the water extract of Clitoria ternatea (liquid).
チョウマメの10%未満のエタノール抽出物は、例えば、チョウマメの粉砕物と10%w/w未満のエタノール水溶液とを混合し、得られた混合液から遠心分離又は濾過などの分離方法によって固形物を分離及び除去することによって得ることができる。1つの実施形態において、チョウマメの10%未満のエタノール抽出物は、チョウマメ(好ましくは花の乾燥物)の粉砕物と、前記粉砕物の10倍重量の10%w/w未満のエタノール水溶液とを混合し、得られた混合液を室温で20分間放置した後、遠心分離又は濾過などの分離方法によって前記混合液から固形物を分離及び除去することによって得ることができる。チョウマメの10%w/w未満のエタノール抽出物は、液体又は固体であってよい。チョウマメの10%w/w未満のエタノール抽出物(固体)は、例えば、チョウマメの10%w/w未満のエタノール抽出物(液体)の凍結乾燥によって調製することができる。チョウマメの10%w/w未満のエタノール抽出物(液体)は、例えば、10%w/w未満のエタノール抽出物(液体)を凍結乾燥などにより固形化して、その固形物を水で溶解した液体であってもよい。 For the ethanol extract of less than 10% of Clitoria ternatea, for example, a pulverized C. elegans and an aqueous ethanol solution of less than 10% w / w are mixed, and a solid substance is separated from the obtained mixed solution by a separation method such as centrifugation or filtration. It can be obtained by separation and removal. In one embodiment, the ethanol extract of less than 10% of Clitoria ternatea is a pulverized product of Clitoria ternatea (preferably dried flower) and an aqueous ethanol solution of less than 10% w / w, which is 10 times the weight of the pulverized product. It can be obtained by mixing and allowing the obtained mixed solution to stand at room temperature for 20 minutes, and then separating and removing solid matter from the mixed solution by a separation method such as centrifugation or filtration. The ethanol extract of less than 10% w / w of Clitoria ternatea may be liquid or solid. The ethanol extract (solid) of less than 10% w / w of Clitoria ternatea can be prepared, for example, by freeze-drying the ethanol extract (liquid) of less than 10% w / w of Clitoria ternatea. The ethanol extract (liquid) of less than 10% w / w of Clitoria ternatea is, for example, a liquid obtained by solidifying the ethanol extract (liquid) of less than 10% w / w by freeze-drying and dissolving the solid in water. May be.
チョウマメのエタノール抽出物は、例えば、8%w/w未満のエタノール、5%w/w未満のエタノール、3%w/w未満のエタノール、又は1%w/w未満のエタノールと、チョウマメの粉砕物とを混合して、得られた混合液から固形物を分離及び除去することによって調製したものであってよい。 Ethanol extract of Clitoria ternatea is, for example, ethanol of less than 8% w / w, ethanol of less than 5% w / w, ethanol of less than 3% w / w, or ethanol of less than 1% w / w, and crushed C. elegans. It may be prepared by mixing with a substance and separating and removing the solid substance from the obtained mixed solution.
「ニオイタコノキ(Pandanus)」は、タコノキ科(Pandanaceae)のタコノキ属(Pandanus)に属する単子葉植物であり、パンダリーフとも称される。ニオイタコノキは、例えば、公知の方法により栽培及び採取でき、又は商業的に入手可能である。1つの実施形態において、ニオイタコノキは、葉、茎、及び根からなる群から選択される少なくとも1つの部位であってよく、好ましくは葉、及び茎のいずれか一方又は両方であり、より好ましくは葉である。ニオイタコノキの重量は、乾燥形態の重量である。 "Pandanus" is a monocotyledonous plant belonging to the genus Pandanaceae of the Pandanaceae family, and is also called panda leaf. Pandanaceae can be cultivated and harvested, for example, by known methods, or are commercially available. In one embodiment, Pandanaceae may be at least one site selected from the group consisting of leaves, stems, and roots, preferably one or both of the leaves and stems, more preferably. It is a leaf. The weight of Pandanaceae is the weight of the dried form.
ニオイタコノキの水抽出物は、例えば、ニオイタコノキの粉砕物と水とを混合し、得られた混合液から遠心分離又は濾過などの分離方法によって固形物を分離及び除去することによって得ることができる。1つの実施形態において、ニオイタコノキ(好ましくは葉の乾燥物)の水抽出物は、ニオイタコノキの粉砕物と、前記粉砕物の10倍重量の水とを混合し、得られた混合液を室温で20分間放置した後、遠心分離又は濾過などの分離方法によって前記混合液から固形物を分離及び除去することによって得ることができる。ニオイタコノキの水抽出物は、液体又は固体であってよい。ニオイタコノキの水抽出物(固体)は、例えば、ニオイタコノキの水抽出物(液体)の凍結乾燥によって調製することができる。 The water extract of Pandanaceae can be obtained, for example, by mixing pulverized Pandanaceae with water and separating and removing the solid matter from the obtained mixed solution by a separation method such as centrifugation or filtration. .. In one embodiment, the water extract of Pandan (preferably dried leaves) is prepared by mixing a pulverized product of Pandan and 10 times the weight of water of the crushed product, and the resulting mixed solution is brought to room temperature. It can be obtained by separating and removing the solid matter from the mixed solution by a separation method such as centrifugation or filtration after leaving it for 20 minutes. The water extract of Pandanaceae may be liquid or solid. The water extract (solid) of Pandanaceae can be prepared, for example, by freeze-drying the water extract (liquid) of Pandanaceae.
ニオイタコノキの10%未満のエタノール抽出物は、例えば、ニオイタコノキの粉砕物と10%w/w未満のエタノール水溶液とを混合し、得られた混合液から遠心分離又は濾過などの分離方法によって固形物を分離及び除去することによって得ることができる。1つの実施形態において、ニオイタコノキの10%未満のエタノール抽出物は、ニオイタコノキ(好ましくは葉の乾燥物)の粉砕物と、前記粉砕物の10倍重量の10%w/w未満のエタノール水溶液とを混合し、得られた混合液を室温で20分間放置した後、遠心分離又は濾過などの分離方法によって前記混合液から固形物を分離及び除去することによって得ることができる。ニオイタコノキの10%w/w未満のエタノール抽出物は、液体又は固体であってよい。ニオイタコノキの10%w/w未満のエタノール抽出物(固体)は、例えば、ニオイタコノキの10%w/w未満のエタノール抽出物(液体)を凍結乾燥によって調製することができる。ニオイタコノキの10%w/w未満のエタノール抽出物(液体)は、例えば、10%w/w未満のエタノール抽出物(液体)を凍結乾燥などにより固形化して、その固形物を水で溶解した液体であってよい。 The ethanol extract of less than 10% of Pandanaceae is obtained by mixing, for example, a pulverized product of Pandanaceae and an aqueous ethanol solution of less than 10% w / w, and solidifying the obtained mixed solution by a separation method such as centrifugation or filtration. It can be obtained by separating and removing objects. In one embodiment, the ethanol extract of less than 10% of Pandan is a pulverized product of Pandan (preferably dried leaves) and an aqueous ethanol solution of less than 10% w / w, which is 10 times the weight of the pulverized product. It can be obtained by mixing and leaving the obtained mixed solution at room temperature for 20 minutes, and then separating and removing the solid matter from the mixed solution by a separation method such as centrifugation or filtration. The ethanol extract of Pandanaceae less than 10% w / w may be liquid or solid. An ethanol extract (solid) of less than 10% w / w of Pandanaceae can be prepared, for example, an ethanol extract (liquid) of less than 10% w / w of Pandanaceae by freeze-drying. For the ethanol extract (liquid) of less than 10% w / w of Pandan, for example, the ethanol extract (liquid) of less than 10% w / w was solidified by freeze-drying or the like, and the solid was dissolved in water. It may be a liquid.
ニオイタコノキのエタノール抽出物は、例えば、8%w/w未満のエタノール、5%w/w未満のエタノール、3%w/w未満のエタノール、又は1%w/w未満のエタノールと、ニオイタコノキの粉砕物とを混合して、得られた混合液から固形物を分離することによって調製したものであってよい。 Ethanol extracts of Pandanaceae include, for example, ethanol of less than 8% w / w, ethanol of less than 5% w / w, ethanol of less than 3% w / w, or ethanol of less than 1% w / w, and Pandanaceae. It may be prepared by mixing with the pulverized product of the above and separating the solid substance from the obtained mixed solution.
「皮膚適用用組成物」は、皮膚に適用し得る形態であればよく、溶液系、乳化系、粉末系、ゲル系、軟膏系、クリーム、ミスト、エアゾール、水−油二層系、又は水−油−粉三層系であってよい。皮膚適用用組成物は、例えば、チョウマメの水抽出物若しくは10%未満のアルコール抽出物、及びニオイタコノキの水抽出物若しくは10%未満のアルコール抽出物のいずれか一方又は両方を、前記組成物の重量当たり95%w/w以下、90%w/w以下、80%w/w以下、70%w/w以下、60%w/w以下、50%w/w以下、40%w/w以下、30%w/w以下、20%w/w以下、10%w/w以下、又は5%w/w以下含む。皮膚適用用組成物は、さらに、皮膚に適用可能な担体又は賦形剤、要すれば、適当な添加剤を適宜含んでよい。皮膚適用用組成物は、公知の方法により調製することができる。一例において、皮膚適用用組成物は、チョウマメの水抽出物若しくは10%未満のアルコール抽出物、及びニオイタコノキの水抽出物若しくは10%未満のアルコール抽出物のいずれか一方又は両方と、皮膚に適用可能な担体又は賦形剤とを混合することにより調製することができる。 The "composition for skin application" may be in a form applicable to the skin, and may be a solution system, an emulsifying system, a powder system, a gel system, an ointment system, a cream, a mist, an aerosol, a water-oil two-layer system, or water. -Oil-powder may be a three-layer system. The composition for skin application is, for example, a water extract of butterfly bean or an alcohol extract of less than 10%, and either or both of a water extract of Pandan or an alcohol extract of less than 10%. 95% w / w or less, 90% w / w or less, 80% w / w or less, 70% w / w or less, 60% w / w or less, 50% w / w or less, 40% w / w or less per weight , 30% w / w or less, 20% w / w or less, 10% w / w or less, or 5% w / w or less. The composition for skin application may further contain a carrier or excipient applicable to the skin and, if necessary, a suitable additive as appropriate. The composition for skin application can be prepared by a known method. In one example, the composition for skin application is applied to the skin with either or both of a water extract of Clitoria ternatea or an alcohol extract of less than 10% and a water extract of Pandan or an alcohol extract of less than 10%. It can be prepared by mixing with a possible carrier or excipient.
「CCN1」は、Cysteine rich 61(Cyr61)としても知られる、CCNファミリーに属するタンパク質である。CCN1は、細胞表面のインテグリン受容体及びヘパラン硫酸プロテオグリカンとの相互作用を通じて、細胞増殖、細胞運動、細胞分化、及び細胞の老化に関与する。CCN1のアミノ酸配列及び核酸配列は公知である。 "CCN1" is a protein belonging to the CCN family, also known as Cysteine rich 61 (Cyr61). CCN1 is involved in cell proliferation, cell motility, cell differentiation, and cell aging through interaction with cell surface integrin receptors and heparan sulfate proteoglycans. The amino acid sequence and nucleic acid sequence of CCN1 are known.
「CCN2」は、結合組織増殖因子(connective tissue growth factor(CTGF))としても知られる、CCNファミリーに属するタンパク質である。CCN2は、線維芽細胞の増殖促進、細胞外気質産生促進、結合組織増殖促進、軟骨細胞の増殖、細胞分化の促進、創傷治癒、及び線維性疾患に関与する。CCN2のアミノ酸配列及び核酸配列は公知である。 "CCN2" is a protein belonging to the CCN family, also known as connective tissue growth factor (CTGF). CCN2 is involved in promoting fibroblast proliferation, promoting extracellular air mass production, promoting connective tissue proliferation, chondrocyte proliferation, promoting cell differentiation, wound healing, and fibrotic diseases. The amino acid and nucleic acid sequences of CCN2 are known.
CCN1及びCCN2の「発現の増加」は、本開示に係る組成物を培養したヒトの皮膚線維芽細胞に添加した場合のCCN1の発現量及びCCN2の発現量が、本開示に係る組成物を添加しなかった場合のCCN1の発現量及びCCN2の発現量と比較して、少なくとも20%、30%、40%、又は50%増加することであってよい。CCN1及びCCN2の発現量は、CCN1又はCCN2に対応する培養したヒト線維芽細胞中のRNAの量を意味する。RNAの量は、本願明細書の実施例に記載のように、RT−PCRにより測定することができる。 The "increased expression" of CCN1 and CCN2 means that the expression level of CCN1 and the expression level of CCN2 when the composition according to the present disclosure is added to cultured human skin fibroblasts is the addition of the composition according to the present disclosure. It may be increased by at least 20%, 30%, 40%, or 50% as compared with the expression level of CCN1 and the expression level of CCN2 when not used. The expression level of CCN1 and CCN2 means the amount of RNA in cultured human fibroblasts corresponding to CCN1 or CCN2. The amount of RNA can be measured by RT-PCR as described in the examples herein.
「肌の老化防止」は、皮膚の弾力が維持される又は向上することを意味する。肌の老化防止は、CCN1及びCCN2の発現が増加し、表皮幹細胞から表皮角化細胞への分化が促進され、表皮幹細胞及び/又は表皮角化細胞の増殖が促進され、真皮幹細胞の増殖及び/又は繊維芽細胞への分化が促進され、或いは線維芽細胞の分化によるコラーゲン、エラスチン、ヒアルロン酸の産生が促進されることによって達成され得る。肌の老化防止は、例えば、本開示に係る組成物をヒトの肌に1日1回〜3回を3週間適用した場合に、本開示に係る組成物を適用しなかった場合と比べて、皮膚の弾力が維持される又は5%以上、10%以上若しくは15%以上向上することであってよい。 "Skin anti-aging" means that the elasticity of the skin is maintained or improved. To prevent skin aging, the expression of CCN1 and CCN2 is increased, the differentiation of epidermal stem cells into epidermal keratinocytes is promoted, the proliferation of epidermal stem cells and / or epidermal keratinocytes is promoted, and the proliferation of dermal stem cells and / Alternatively, it can be achieved by promoting the differentiation into fibroblasts, or by promoting the production of collagen, elastin, and hyaluronic acid by the differentiation of fibroblasts. For skin aging prevention, for example, when the composition according to the present disclosure is applied to human skin once to three times a day for 3 weeks, as compared with the case where the composition according to the present disclosure is not applied. The elasticity of the skin may be maintained or improved by 5% or more, 10% or more or 15% or more.
「創傷治癒」は、創傷治癒が促進させることを意味する。創傷治癒は、CCN1及びCCN2の発現が増加し、線維芽細胞の増殖が促進され、或いは表皮細胞が遊走及び増殖することによって達成され得る。創傷治癒は、例えば、本開示に係る組成物を皮膚の創傷に適用した場合、本開示に係る組成物を同程度の皮膚の創傷に適用しなかった場合と比べて、創傷治癒が促進されることであってよい。 "Wound healing" means that wound healing is promoted. Wound healing can be achieved by increased expression of CCN1 and CCN2, accelerated proliferation of fibroblasts, or migration and proliferation of epidermal cells. Wound healing is enhanced, for example, when the composition according to the present disclosure is applied to a wound on the skin, as compared to when the composition according to the present disclosure is not applied to a wound on the same degree of skin. It may be that.
「発毛促進」は、発毛が促進させることを意味する。毛髪促進は、CCN1及びCCN2の発現が増加し、毛包幹細胞から毛乳頭細胞への分化が促進され、或いは毛包幹細胞及び/又は毛乳頭細胞の増殖が促進されることによって達成され得る。発毛促進は、例えば、本開示に係る組成物を頭皮に適用した場合、本開示に係る組成物を適用する前と比べて、当該頭皮における毛髪が増加することであってよい。 "Promoting hair growth" means promoting hair growth. Hair promotion can be achieved by increasing the expression of CCN1 and CCN2, promoting the differentiation of hair follicle stem cells into hair papilla cells, or promoting the proliferation of hair follicle stem cells and / or hair papilla cells. The promotion of hair growth may be, for example, when the composition according to the present disclosure is applied to the scalp, the hair on the scalp is increased as compared with the case before the composition according to the present disclosure is applied.
1つの実施形態において、本開示に係る皮膚適用用組成物は、肌の老化防止、創傷治癒用、又は発毛促進用であり、好ましくは肌の老化防止又は創傷治癒用であり、より好ましくは肌の老化防止用である。 In one embodiment, the skin-applied composition according to the present disclosure is for skin aging prevention, wound healing, or hair growth promotion, preferably for skin aging prevention or wound healing, and more preferably. It is for preventing skin aging.
以下、具体的な実施例を記載するが、それらは本発明の好ましい実施形態を示すものであり、添付する特許請求の範囲に記載の発明をいかようにも限定するものではない。 Specific examples will be described below, but they show preferred embodiments of the present invention and do not limit the inventions described in the appended claims in any way.
[調製例]
以下の表に記載のNo.1〜No.8に対応する植物試料の乾燥物2gを、すり鉢とすりこぎ棒とを用いて又は袋に詰めて叩くことによって、それぞれ粉砕した。粉砕した各植物試料と水20mlと混合した。得られた混合液を20分間室温下で放置した。前記混合液を遠心分離(3000回転、10分)にかけ、上清を各植物試料の水抽出物(比較例1〜6、実施例1及び2)とした。
[Preparation example]
No. in the table below. 1-No. 2 g of the dried plant sample corresponding to No. 8 was crushed by using a mortar and a pestle or by packing in a bag and tapping. Each crushed plant sample was mixed with 20 ml of water. The obtained mixed solution was left at room temperature for 20 minutes. The mixed solution was centrifuged (3000 rpm, 10 minutes), and the supernatant was used as an aqueous extract of each plant sample (Comparative Examples 1 to 6, Examples 1 and 2).
以下の表に記載のNo.1〜No.8に対応する植物試料の乾燥物2gを、すり鉢とすりこぎ棒とを用いて又は袋に詰めて叩くことによって、それぞれ粉砕した。粉砕した各植物試料と70%エタノール20mlと混合した。上記と同様にして、得られた混合液から各植物試料のエタノール抽出物(比較例7〜14)を得た。
No. in the table below. 1-No. 2 g of the dried plant sample corresponding to No. 8 was crushed by using a mortar and a pestle or by packing in a bag and tapping. Each crushed plant sample was mixed with 20 ml of 70% ethanol. In the same manner as above, ethanol extracts (Comparative Examples 7-14) of each plant sample were obtained from the obtained mixed solution.
[細胞培養]
ヒトの皮膚線維芽細胞を、培養液3mlを含むシャーレにて培養した。前記培養液に、比較例1の水抽出物を0.25ml添加した。比較例2〜6、実施例1及び実施例2の各水抽出物0.25mlを前記培養液に添加した。対照として、水0.25mlを用いた(C1)。同様にして、前記培養液に、比較例7〜14の各エタノール抽出物0.25mlを前記培養液に添加した。対照として、70%エタノール0.25mlを用いた(C2)。前記皮膚線維芽細胞を、各抽出物が添加された培養液中、37℃、5%CO2下にてさらに24時間培養した。
[Cell culture]
Human skin fibroblasts were cultured in a petri dish containing 3 ml of culture medium. 0.25 ml of the water extract of Comparative Example 1 was added to the culture broth. 0.25 ml of each water extract of Comparative Examples 2 to 6, Examples 1 and 2 was added to the culture broth. As a control, 0.25 ml of water was used (C1). Similarly, 0.25 ml of each ethanol extract of Comparative Examples 7 to 14 was added to the culture broth. As a control, 0.25 ml of 70% ethanol was used (C2). The skin fibroblasts were further cultured for 24 hours at 37 ° C. under 5% CO 2 in the culture medium to which each extract was added.
さらなる培養後に、各シャーレからヒト皮膚線維芽細胞を回収した。回収したヒト皮膚線維芽細胞におけるCCN1及びCCN2の発現量を、Applied Biosystems 7000 Sequence Detection Systemを用いたRT−PCTにより定量した。RT−PCRは、One Step TB Green(登録商標)PrimeScript(商標)RT−PCR Kitを用い、前記キットに添付の説明書に従って行った。CCN1のRT−PCRには、配列番号1及び2に記載の各核酸配列を有するプライマーを用いた。CCN2のRT−PCRには、配列番号3及び4に記載の各核酸配列を有するプライマーを用いた。 After further culture, human skin fibroblasts were harvested from each petri dish. The expression levels of CCN1 and CCN2 in the recovered human skin fibroblasts were quantified by RT-PCT using Applied Biosystems 7000 Sequence Detection System. RT-PCR was performed using the One Step TB Green® PrimeScript ™ RT-PCR Kit according to the instructions attached to the kit. For RT-PCR of CCN1, primers having each nucleic acid sequence shown in SEQ ID NOs: 1 and 2 were used. For RT-PCR of CCN2, primers having each nucleic acid sequence shown in SEQ ID NOs: 3 and 4 were used.
[結果]
各植物試料(No.1〜No.8)の水抽出物を用いた場合のCCN1発現量から、対照C1を用いた場合のCCN1発現量に対する相対値を算出した。算出した結果を図1に示す。図1は、植物試料No.1〜No.3、及びNo.5が、対照C1と比較して、CCN1の発現量を増加させたことを示す。
[result]
From the CCN1 expression level when the water extract of each plant sample (No. 1 to No. 8) was used, a relative value with respect to the CCN1 expression level when the control C1 was used was calculated. The calculated result is shown in FIG. FIG. 1 shows the plant sample No. 1-No. 3 and No. 5 shows that the expression level of CCN1 was increased as compared with the control C1.
各植物試料(No.1〜No.8)の70%エタノール抽出物を用いた場合のCCN1発現量から、対照C2を用いた場合のCCN1発現量に対する相対値を算出した。算出した結果を図2に示す。図2は、植物試料No.1、及びNo.3〜No.8が、対照C2と比較して、CCN1の発現量を増加させたことを示す。 From the CCN1 expression level when the 70% ethanol extract of each plant sample (No. 1 to No. 8) was used, a relative value with respect to the CCN1 expression level when the control C2 was used was calculated. The calculated result is shown in FIG. FIG. 2 shows the plant sample No. 1 and No. 3 to No. 8 shows that the expression level of CCN1 was increased as compared with the control C2.
図1及び図2は、植物試料No.1、No.3及びNo.5が、水抽出物及び70%エタノール抽出物の両方が、対照C1及びC2と比べて、CCN1の発現量をそれぞれ増加させたことを示した。図1及び図2は、また、植物試料No.2が、水抽出物の場合にはCCN1の発現を増加させるが、70%エタノール抽出物の場合はCCN1の発現を低下させることを示す。 1 and 2 show the plant sample No. 1, No. 3 and No. 5 showed that both the water extract and the 70% ethanol extract increased the expression level of CCN1 as compared to controls C1 and C2, respectively. 1 and 2 also show the plant sample No. 2 shows that in the case of a water extract, the expression of CCN1 is increased, but in the case of a 70% ethanol extract, the expression of CCN1 is decreased.
各植物試料(No.1〜No.8)の水抽出物を用いた場合のCCN2発現量から、対照C1を用いた場合のCCN2発現量に対する相対値を算出した。算出した結果を図3に示す。図3は、植物試料No.2、No.3、及びNo.8が、対照C1と比較して、CCN2の発現量を増加させたことを示す。 From the CCN2 expression level when the water extract of each plant sample (No. 1 to No. 8) was used, a relative value with respect to the CCN2 expression level when the control C1 was used was calculated. The calculated result is shown in FIG. FIG. 3 shows the plant sample No. 2. No. 3 and No. 8 shows that the expression level of CCN2 was increased as compared with the control C1.
各植物試料(No.1〜No.8)の70%エタノール抽出物を用いた場合のCCN2発現量から、対照C2を用いた場合のCCN2発現量に対する相対値を算出した。算出した結果を図4に示す。図4は、植物試料No.1が、対照C2と比較して、CCN2の発現量を増加させたことを示す。 From the CCN2 expression level when the 70% ethanol extract of each plant sample (No. 1 to No. 8) was used, a relative value with respect to the CCN2 expression level when the control C2 was used was calculated. The calculated result is shown in FIG. FIG. 4 shows the plant sample No. 1 indicates that the expression level of CCN2 was increased as compared with the control C2.
図3及び図4は、植物試料No.2、No.3及びNo.8が、水抽出物の場合にはCCN2の発現を増加させるが、70%エタノール抽出物の場合はCCN2の発現を低下させることを示す。 3 and 4 show the plant sample No. 2. No. 3 and No. 8 shows that in the case of a water extract, the expression of CCN2 is increased, but in the case of a 70% ethanol extract, the expression of CCN2 is decreased.
図1〜図4は、No.2及びNo.3の水抽出物が、対照C1及びC2と比較して、CCN1及びCCN2それぞれに発現量を増加させたことを示す。 1 to 4 show No. 2 and No. It is shown that the water extract of No. 3 increased the expression level of CCN1 and CCN2, respectively, as compared with the controls C1 and C2.
Claims (2)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020111472A JP6978015B1 (en) | 2020-06-29 | 2020-06-29 | Composition for skin application to increase the expression of CCN1 and CCN2 |
PCT/JP2021/024386 WO2022004669A1 (en) | 2020-06-29 | 2021-06-28 | Composition for application to skin to increase expression of ccn1 and ccn2 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020111472A JP6978015B1 (en) | 2020-06-29 | 2020-06-29 | Composition for skin application to increase the expression of CCN1 and CCN2 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6978015B1 true JP6978015B1 (en) | 2021-12-08 |
JP2022022590A JP2022022590A (en) | 2022-02-07 |
Family
ID=78815542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020111472A Active JP6978015B1 (en) | 2020-06-29 | 2020-06-29 | Composition for skin application to increase the expression of CCN1 and CCN2 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6978015B1 (en) |
WO (1) | WO2022004669A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024057970A1 (en) * | 2022-09-14 | 2024-03-21 | 株式会社 資生堂 | Composition comprising green tea extract, for promoting expression of ccn2 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002121110A (en) * | 2000-10-12 | 2002-04-23 | Kyoei Kagaku Kogyo Kk | Cosmetic |
JP2003267851A (en) * | 2002-03-14 | 2003-09-25 | Noevir Co Ltd | Skin care preparation |
JP2004043393A (en) * | 2002-07-15 | 2004-02-12 | Noevir Co Ltd | Vascular endothelial cell growth factor production promoter |
JP2004043392A (en) * | 2002-07-15 | 2004-02-12 | Noevir Co Ltd | Preparation for external use for scalp and hair |
JP2007016003A (en) * | 2005-07-11 | 2007-01-25 | Toyo Ink Mfg Co Ltd | Antioxidant |
JP2008162897A (en) * | 2006-12-27 | 2008-07-17 | Toyo Ink Mfg Co Ltd | Hair care preparation |
US20120269914A1 (en) * | 2009-03-27 | 2012-10-25 | Rudy Susilo | Plant extracts for treating skin diseases |
JP2013515054A (en) * | 2009-12-22 | 2013-05-02 | エイボン プロダクツ インコーポレーテッド | Paxillin stimulating composition and its use as a cosmetic |
CN108578294A (en) * | 2018-06-17 | 2018-09-28 | 佛山文森特知识产权服务有限公司 | A kind of skin care compositions and cosmetics promoting effect of skin-lifting and moisture-keeping efficacy |
-
2020
- 2020-06-29 JP JP2020111472A patent/JP6978015B1/en active Active
-
2021
- 2021-06-28 WO PCT/JP2021/024386 patent/WO2022004669A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002121110A (en) * | 2000-10-12 | 2002-04-23 | Kyoei Kagaku Kogyo Kk | Cosmetic |
JP2003267851A (en) * | 2002-03-14 | 2003-09-25 | Noevir Co Ltd | Skin care preparation |
JP2004043393A (en) * | 2002-07-15 | 2004-02-12 | Noevir Co Ltd | Vascular endothelial cell growth factor production promoter |
JP2004043392A (en) * | 2002-07-15 | 2004-02-12 | Noevir Co Ltd | Preparation for external use for scalp and hair |
JP2007016003A (en) * | 2005-07-11 | 2007-01-25 | Toyo Ink Mfg Co Ltd | Antioxidant |
JP2008162897A (en) * | 2006-12-27 | 2008-07-17 | Toyo Ink Mfg Co Ltd | Hair care preparation |
US20120269914A1 (en) * | 2009-03-27 | 2012-10-25 | Rudy Susilo | Plant extracts for treating skin diseases |
JP2013515054A (en) * | 2009-12-22 | 2013-05-02 | エイボン プロダクツ インコーポレーテッド | Paxillin stimulating composition and its use as a cosmetic |
CN108578294A (en) * | 2018-06-17 | 2018-09-28 | 佛山文森特知识产权服务有限公司 | A kind of skin care compositions and cosmetics promoting effect of skin-lifting and moisture-keeping efficacy |
Non-Patent Citations (2)
Title |
---|
BANSEI AYURVEDA, JAPAN: "Ceylon Tea & Citron Bath & Massage Oil", MINTEL GNPD [ONLINE], JPN6020040854, November 2017 (2017-11-01), ISSN: 0004545407 * |
WANDER BEAUTY, USA: "Staycation Hydrating Mask", MINTEL GNPD [ONLINE], JPN6020040851, May 2020 (2020-05-01), ISSN: 0004545406 * |
Also Published As
Publication number | Publication date |
---|---|
WO2022004669A1 (en) | 2022-01-06 |
JP2022022590A (en) | 2022-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104812368B (en) | Dedifferente the beautifying use of plant cell | |
KR100853761B1 (en) | Extract of Stewartia koreana and Use Thereof | |
CN109152724B (en) | Synergistic extract of palmaria palmiformis and jasmine, composition containing synergistic extract and application of synergistic extract | |
KR102294818B1 (en) | Composition for skin regeneration and moisturing comprising starfish extracts | |
KR20110090803A (en) | Cosmetic composition | |
KR102113645B1 (en) | A cosmetic composition for preventing hair loss and promoting hair growth containing spicule powder and natural extract | |
KR20110119062A (en) | Enriched media of human adipose tissue-derived stem cells having skin regeneration or antiwrinkle effect and uses thereof | |
JP6978015B1 (en) | Composition for skin application to increase the expression of CCN1 and CCN2 | |
KR101124971B1 (en) | Cosmetic composition containing Salicornia herbacea callus Extracts and Laminaria digitata Extracts for Improving Skin Wrinkle or enhancing skin Elasticity | |
KR20100096447A (en) | Cosmetic composition comprising matrials cultured adult stem cells derived from swine placenta tissue and proteins extracted therefrom | |
KR101798632B1 (en) | Cosmetic composition containing stellera chamaejasme extract or fraction thereof and use thereof | |
KR101872357B1 (en) | Cosmetic composition for enhancing skin elasticity containing extract of rhamnus yoshinoi | |
KR20170055172A (en) | Cosmetic Composition Comprising Extracts of Centipeda minima | |
KR102509224B1 (en) | Fuctional cosmetic composition | |
KR102369110B1 (en) | Cosmetic composition containing the mixed extract of Kummerowia stipulacea and Tephroseris kirilowii | |
KR102508159B1 (en) | Cosmetic Composition for Preventing Skin Aging and Improving Skin Winkle comprising Extract of Viburnum stellato-tomentosum | |
KR101679391B1 (en) | Composition for treating wound containing stellera chamaejasme extract or fraction thereof and method for treating wound in a subject | |
KR101618726B1 (en) | Method for making protein from Pollock skin | |
KR101597762B1 (en) | Composition for treating wound containing stellera chamaejasme extract or fraction thereof and method for treating wound in a subject | |
KR102082676B1 (en) | Composition for hair care | |
KR20220153271A (en) | Composition for preventing forming scar comprising exosome derived from milk as an active ingredient | |
JP6901256B2 (en) | Epithelial cell activator | |
KR101944494B1 (en) | Cosmetic composition comprising extract of Trachelospermum species comprising Trachelospermum jasminoides as active ingredient | |
JP6561135B2 (en) | COMPOSITION FOR TREATING Wounds, INCLUDING NUOXIN EXTRACT OR ITS FRANCIFIED AND METHOD OF TREATING Wounds of Individuals | |
KR102248170B1 (en) | Composition for skin regeneration and wound healing comprising the extract of actinidia chinensis stem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200811 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200811 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200901 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210309 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210507 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210910 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211026 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211102 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6978015 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |